AN2 THERAPEUTICS INC (ANTX) Fundamental Analysis & Valuation

NASDAQ:ANTX • US0373261058

Current stock price

4.68 USD
+0.13 (+2.86%)
At close:
4.68 USD
0 (0%)
After Hours:

This ANTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ANTX Profitability Analysis

1.1 Basic Checks

  • ANTX had negative earnings in the past year.
  • In the past year ANTX has reported a negative cash flow from operations.
  • ANTX had negative earnings in each of the past 5 years.
  • In the past 5 years ANTX always reported negative operating cash flow.
ANTX Yearly Net Income VS EBIT VS OCF VS FCFANTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -56.78%, ANTX is doing worse than 68.59% of the companies in the same industry.
  • ANTX has a Return On Equity (-66.29%) which is in line with its industry peers.
Industry RankSector Rank
ROA -56.78%
ROE -66.29%
ROIC N/A
ROA(3y)-53.05%
ROA(5y)-48.77%
ROE(3y)-60.3%
ROE(5y)-54.22%
ROIC(3y)N/A
ROIC(5y)N/A
ANTX Yearly ROA, ROE, ROICANTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • ANTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANTX Yearly Profit, Operating, Gross MarginsANTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ANTX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ANTX has been reduced compared to 1 year ago.
  • ANTX has more shares outstanding than it did 5 years ago.
  • ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANTX Yearly Shares OutstandingANTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ANTX Yearly Total Debt VS Total AssetsANTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • ANTX has an Altman-Z score of 4.55. This indicates that ANTX is financially healthy and has little risk of bankruptcy at the moment.
  • ANTX's Altman-Z score of 4.55 is fine compared to the rest of the industry. ANTX outperforms 71.20% of its industry peers.
  • There is no outstanding debt for ANTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.55
ROIC/WACCN/A
WACCN/A
ANTX Yearly LT Debt VS Equity VS FCFANTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • ANTX has a Current Ratio of 6.87. This indicates that ANTX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ANTX (6.87) is better than 72.77% of its industry peers.
  • ANTX has a Quick Ratio of 6.87. This indicates that ANTX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.87, ANTX is doing good in the industry, outperforming 73.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.87
Quick Ratio 6.87
ANTX Yearly Current Assets VS Current LiabilitesANTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ANTX Growth Analysis

3.1 Past

  • ANTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.27%, which is quite impressive.
EPS 1Y (TTM)29.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -5.12% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.98%
EPS Next 2Y13.87%
EPS Next 3Y-3.48%
EPS Next 5Y-5.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANTX Yearly EPS VS EstimatesANTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ANTX Valuation Analysis

4.1 Price/Earnings Ratio

  • ANTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANTX Price Earnings VS Forward Price EarningsANTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANTX Per share dataANTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • ANTX's earnings are expected to decrease with -3.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.87%
EPS Next 3Y-3.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANTX Dividend Analysis

5.1 Amount

  • ANTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANTX Fundamentals: All Metrics, Ratios and Statistics

AN2 THERAPEUTICS INC

NASDAQ:ANTX (5/1/2026, 8:09:40 PM)

After market: 4.68 0 (0%)

4.68

+0.13 (+2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)03-17
Earnings (Next)05-13
Inst Owners51.46%
Inst Owner Change0%
Ins Owners8.86%
Ins Owner Change7.26%
Market Cap168.20M
Revenue(TTM)N/A
Net Income(TTM)-35.17M
Analysts43.33
Price Target1.02 (-78.21%)
Short Float %2.22%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.31%
Min EPS beat(2)-38.15%
Max EPS beat(2)-18.46%
EPS beat(4)1
Avg EPS beat(4)-12.63%
Min EPS beat(4)-38.15%
Max EPS beat(4)38.17%
EPS beat(8)5
Avg EPS beat(8)-0.44%
EPS beat(12)7
Avg EPS beat(12)1.07%
EPS beat(16)9
Avg EPS beat(16)-28.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.17
P/tB 3.17
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0
BVpS1.48
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -56.78%
ROE -66.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.05%
ROA(5y)-48.77%
ROE(3y)-60.3%
ROE(5y)-54.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.87
Quick Ratio 6.87
Altman-Z 4.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
EPS Next Y19.98%
EPS Next 2Y13.87%
EPS Next 3Y-3.48%
EPS Next 5Y-5.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.43%
OCF growth 3YN/A
OCF growth 5YN/A

AN2 THERAPEUTICS INC / ANTX Fundamental Analysis FAQ

What is the fundamental rating for ANTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANTX.


What is the valuation status for ANTX stock?

ChartMill assigns a valuation rating of 0 / 10 to AN2 THERAPEUTICS INC (ANTX). This can be considered as Overvalued.


Can you provide the profitability details for AN2 THERAPEUTICS INC?

AN2 THERAPEUTICS INC (ANTX) has a profitability rating of 0 / 10.


How financially healthy is AN2 THERAPEUTICS INC?

The financial health rating of AN2 THERAPEUTICS INC (ANTX) is 8 / 10.


Can you provide the expected EPS growth for ANTX stock?

The Earnings per Share (EPS) of AN2 THERAPEUTICS INC (ANTX) is expected to grow by 19.98% in the next year.